Mu Opioid Receptor 1 Expression and Activation Patterns in Colorectal Cancer
NCT ID: NCT04353882
Last Updated: 2020-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
20 participants
OBSERVATIONAL
2020-06-01
2022-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MOR-1 Expression in Colorectal Cancer and Disease-free Survival Relationship. Five-year Follow-up.
NCT03601351
Gut Microbiome Modification Through Dietary Intervention in Patients With Colorectal Cancer: Response to Surgery
NCT04869956
A Cohort of Molecular Characteristics and Prognosis of Colorectal Cancer
NCT05086601
Molecular Pathology of Colorectal Cancer: Investigating the Role of Novel Molecular Profiles, microRNA's, and Their Targets in Colorectal Cancer Progression
NCT03309722
Evaluation of Some Risk Factors Associated With Colorectal Cancer
NCT05170360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with tumor recurrence
Assess the difference in MOR-1 expression between healthy and tumor tissue
Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
patients with-out tumor recurrence
Assess the difference in MOR-1 expression between healthy and tumor tissue
Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Assess the difference in MOR-1 expression between healthy and tumor tissue
Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Colorectal surgery scheduled between January 2010 - December 2014.
* Stage II or III colon or rectum neoplasm (T3 / T4 N + M0).
Exclusion Criteria
* Non-oncological colorectal surgery.
* Urgent surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitario La Fe
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oscar Diaz-Cambronero
Principal Investigator of Anesthesiology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MOROCCO-II
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.